New psoriasis pill shows promise in Mid-Stage trial
NCT ID NCT06278350
First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 22 times
Summary
This study tested an experimental drug called D-2570 in 161 adults with moderate-to-severe plaque psoriasis. Participants received either the drug or a placebo for 12 weeks. The main goal was to see if the drug could clear at least 75% of skin plaques. This is a disease-control study, meaning the treatment aims to manage symptoms rather than cure the condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking University People's Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.